Y-ECCO
@y_ecco_ibd
Y-ECCO committee members tweeting about IBD educational and research news. Any views expressed are personal and not official ECCO position.
ID: 749624625441759232
https://www.ecco-ibd.eu 03-07-2016 15:23:32
2,2K Tweet
3,3K Takipçi
3,3K Takip Edilen
1/ ⏰ for #EBGI Tweetorial🧵w/ Aimen Farooq! “Risankizumab Is Superior to Ustekinumab for Induction and Maintenance of Crohn’s Disease: The SEQUENCE Trial” 📰 bit.ly/4cF6tbR 🎧 bit.ly/4dDqL6T 📜 bit.ly/3MlAGCf
#GUTVideo from the paper by Gabriels et al entitled "Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease" via bit.ly/3T0vNCt Paper: bit.ly/3YIzWP0 wouter nagengast Research UMCG #IBD
In contrast to previous reports we found limited predictive value of the gut #microbiome (and #metabolome) for response to biological therapy in #IBD Still small sample sizes but relatively similar to other studies. groningen_microbiome UMCG MDL Research UMCG www-tandfonline-com.proxy-ub.rug.nl/doi/full/10.10…
Intestinal ultrasound is an emerging tool for the management of IBD. Read this article on how a rapid access intestinal ultrasound service may influence patient management Gio McGinty James Kennedy Vivek Goodoory Philip Dunne Mohsen Subhani Rex Wan-Hin Hui Mark Beattie Phil Smith
Distinct and different barriers to IBD care in different regions of the world 🌎 Thank you David Choi, PharmD for highlighting some of the major problems in the USA below - delaying access to effective treatments🤯
How often during a colonoscopy in a patient w #CD could we have missed lesions that would have led to a change in therapy? I’ve wondered about this many times Virginia Solitano addresses it in her 📄 🔍 22.3% had lesions proximal to the TI 🔍 24.5% SB skip lesions in the ileum 🔍
New research - Choy et al Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial thelancet.com/journals/langa… #IBD #GITwitter Matthew Choy Christopher Li Wai Suen
Effectiveness of #ustekinumab in #Crohn’s #disease (#mucosal #healing, fistulas, extraintestinal manifestations & quality of life) was better than in the registration trial program a new national prospective clinical practice study shows Nature Portfolio: nature.com/articles/s4159…
We are happy to announce an IBUS endorsed symposium in Egypt in collaboration with the Egyptian Society of Crohn's and Colitis (ESCCO) next week on September 12th. More information: escco-eg.org/workshop-regis… ESCCO_Society Frauke Petersen #IBUS #ESCCO #IUS #IBD
Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: the ERIC study CD patients from Saint-Antoine and Beaujon Hospital comparing Early vs Late resections onlinelibrary.wiley.com/doi/10.1111/ap… roypounder.apt Philippe Seksik Julien Kirchgesner Harry Sokol
Another really nice study highlighting the crucial importance of early effective intervention in Crohn's disease 👏👏 Timing matters & seems to be critical for best patient outcomes⏲️ Great work by Nathan Grellier Julien Kirchgesner Mathieu Uzzan Harry Sokol and colleagues 🇫🇷